IGF-1 LR3 vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Teriparatide |
|---|---|---|
| Dose Range | 20 mcg–100 mcg | 20 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–6 weeks | 52–104 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
IGF-1 LR3, Teriparatide are both commonly used for:
Key Differences
Unique to IGF-1 LR3:
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | IGF-1 LR3 | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
IGF-1 LR3
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
American journal of physiology. Endocrinology and metabolism, 2025
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
International journal of biological macromolecules, 2025
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
Journal of developmental origins of health and disease, 2023
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?